Review



scfv-hfc antibodies  (ACROBiosystems)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    ACROBiosystems scfv-hfc antibodies
    Scfv Hfc Antibodies, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/scfv-hfc antibodies/product/ACROBiosystems
    Average 90 stars, based on 1 article reviews
    scfv-hfc antibodies - by Bioz Stars, 2026-03
    90/100 stars

    Images



    Similar Products

    scfv-hfc antibodies  (ACROBiosystems)
    90
    ACROBiosystems scfv-hfc antibodies
    Scfv Hfc Antibodies, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/scfv-hfc antibodies/product/ACROBiosystems
    Average 90 stars, based on 1 article reviews
    scfv-hfc antibodies - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    b7 h3 scfv hfc  (Proteintech)
    93
    Proteintech b7 h3 scfv hfc
    Expression of CD70 and <t>B7-H3</t> on human tumor tissues. (A) Representative images of IHC staining of CD70 and B7-H3 on human tumor tissue microarrays were shown. (Scale bar, 20 μm) (B) IHC result of CD70 and B7-H3 staining in normal tissues including brain, esophagus, stomach, intestine, pancreas, appendix. The representative images were shown. (Scale bar, 50 μm) (C) Differential expression profile analysis of B7-H3 and CD70 in tumor and normal tissues based on the TCGA database.
    B7 H3 Scfv Hfc, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/b7 h3 scfv hfc/product/Proteintech
    Average 93 stars, based on 1 article reviews
    b7 h3 scfv hfc - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    b7 h3 scfv hfc chimeric proteins  (Proteintech)
    93
    Proteintech b7 h3 scfv hfc chimeric proteins
    Expression of CD70 and <t>B7-H3</t> on human tumor tissues. (A) Representative images of IHC staining of CD70 and B7-H3 on human tumor tissue microarrays were shown. (Scale bar, 20 μm) (B) IHC result of CD70 and B7-H3 staining in normal tissues including brain, esophagus, stomach, intestine, pancreas, appendix. The representative images were shown. (Scale bar, 50 μm) (C) Differential expression profile analysis of B7-H3 and CD70 in tumor and normal tissues based on the TCGA database.
    B7 H3 Scfv Hfc Chimeric Proteins, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/b7 h3 scfv hfc chimeric proteins/product/Proteintech
    Average 93 stars, based on 1 article reviews
    b7 h3 scfv hfc chimeric proteins - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Expression of CD70 and B7-H3 on human tumor tissues. (A) Representative images of IHC staining of CD70 and B7-H3 on human tumor tissue microarrays were shown. (Scale bar, 20 μm) (B) IHC result of CD70 and B7-H3 staining in normal tissues including brain, esophagus, stomach, intestine, pancreas, appendix. The representative images were shown. (Scale bar, 50 μm) (C) Differential expression profile analysis of B7-H3 and CD70 in tumor and normal tissues based on the TCGA database.

    Journal: Theranostics

    Article Title: Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors

    doi: 10.7150/thno.43991

    Figure Lengend Snippet: Expression of CD70 and B7-H3 on human tumor tissues. (A) Representative images of IHC staining of CD70 and B7-H3 on human tumor tissue microarrays were shown. (Scale bar, 20 μm) (B) IHC result of CD70 and B7-H3 staining in normal tissues including brain, esophagus, stomach, intestine, pancreas, appendix. The representative images were shown. (Scale bar, 50 μm) (C) Differential expression profile analysis of B7-H3 and CD70 in tumor and normal tissues based on the TCGA database.

    Article Snippet: Tumor cell surface expression of CD70 and B7-H3 were detected using CD70 scFv.mFc and B7-H3 scFv.hFc chimeric proteins followed by Cy3-conjuncted goat anti-mouse Fc (Proteintech) for CD70 scFv.hFc and Alexa Fluor 594-conjugated goat anti-human Fc (Jackson ImmunoResearch) for B7-H3 scFv.hFc.

    Techniques: Expressing, Immunohistochemistry, Staining

    Expression of CD70 and B7-H3 in human solid tumor cell lines. (A, B) Representative images showed the immunofluorescence staining of B7-H3 and CD70 together with DAPI in NCI-H460, A375, MDA-MB-435 and 786-O tumor cells. (Scale bar: 20 μm) (C, D) Flow cytometry result indicated high expression of CD70 and B7-H3 on the four solid tumor cell lines.

    Journal: Theranostics

    Article Title: Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors

    doi: 10.7150/thno.43991

    Figure Lengend Snippet: Expression of CD70 and B7-H3 in human solid tumor cell lines. (A, B) Representative images showed the immunofluorescence staining of B7-H3 and CD70 together with DAPI in NCI-H460, A375, MDA-MB-435 and 786-O tumor cells. (Scale bar: 20 μm) (C, D) Flow cytometry result indicated high expression of CD70 and B7-H3 on the four solid tumor cell lines.

    Article Snippet: Tumor cell surface expression of CD70 and B7-H3 were detected using CD70 scFv.mFc and B7-H3 scFv.hFc chimeric proteins followed by Cy3-conjuncted goat anti-mouse Fc (Proteintech) for CD70 scFv.hFc and Alexa Fluor 594-conjugated goat anti-human Fc (Jackson ImmunoResearch) for B7-H3 scFv.hFc.

    Techniques: Expressing, Immunofluorescence, Staining, Flow Cytometry

    Construct of CAR (A) Schematic diagrams showing the composition of the four CARs used in this study: CD70 CAR 1 , CD70 CAR 2 , B7-H3 CAR and TanCAR. (B) The lentiviral backbone plasmid encodes the TanCAR. (C) Cartoon depicted of TanCAR targeting respective tumor antigens.

    Journal: Theranostics

    Article Title: Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors

    doi: 10.7150/thno.43991

    Figure Lengend Snippet: Construct of CAR (A) Schematic diagrams showing the composition of the four CARs used in this study: CD70 CAR 1 , CD70 CAR 2 , B7-H3 CAR and TanCAR. (B) The lentiviral backbone plasmid encodes the TanCAR. (C) Cartoon depicted of TanCAR targeting respective tumor antigens.

    Article Snippet: Tumor cell surface expression of CD70 and B7-H3 were detected using CD70 scFv.mFc and B7-H3 scFv.hFc chimeric proteins followed by Cy3-conjuncted goat anti-mouse Fc (Proteintech) for CD70 scFv.hFc and Alexa Fluor 594-conjugated goat anti-human Fc (Jackson ImmunoResearch) for B7-H3 scFv.hFc.

    Techniques: Construct, Plasmid Preparation

    Functional analysis of CD70 CAR 1 and CD70 CAR 2 . (A) To assess the affinity of two CD70 binding fragments, immunofluorescence was performed using human trCD27.mFc and CD70 scFv.hFc chimeric protein as the primary antibody. Images showed the immunofluorescence staining of CD70 by NCI-H460 and A375 tumor cells. (Scale bar: 20 μm) (B) 4-hour 51 Cr cytotoxicity assays indicated a higher tumor killing of CD70 CAR 2 -T cells against target cells. (C) Microscopy images were captured 8 hours after A375 or H460 cells cocultured with CD70 CAR 1 , CD70 CAR 2 and NT T cells at a ratio of 2 effector cell to 1 target cells. (Scale bar: 50 μm) (D) ELISA results showed the IFN-γ and IL-2 secretion levels by CD70 CAR 1 , CD70 CAR2 and NT T cells encountering A375 or H460 cells.

    Journal: Theranostics

    Article Title: Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors

    doi: 10.7150/thno.43991

    Figure Lengend Snippet: Functional analysis of CD70 CAR 1 and CD70 CAR 2 . (A) To assess the affinity of two CD70 binding fragments, immunofluorescence was performed using human trCD27.mFc and CD70 scFv.hFc chimeric protein as the primary antibody. Images showed the immunofluorescence staining of CD70 by NCI-H460 and A375 tumor cells. (Scale bar: 20 μm) (B) 4-hour 51 Cr cytotoxicity assays indicated a higher tumor killing of CD70 CAR 2 -T cells against target cells. (C) Microscopy images were captured 8 hours after A375 or H460 cells cocultured with CD70 CAR 1 , CD70 CAR 2 and NT T cells at a ratio of 2 effector cell to 1 target cells. (Scale bar: 50 μm) (D) ELISA results showed the IFN-γ and IL-2 secretion levels by CD70 CAR 1 , CD70 CAR2 and NT T cells encountering A375 or H460 cells.

    Article Snippet: Tumor cell surface expression of CD70 and B7-H3 were detected using CD70 scFv.mFc and B7-H3 scFv.hFc chimeric proteins followed by Cy3-conjuncted goat anti-mouse Fc (Proteintech) for CD70 scFv.hFc and Alexa Fluor 594-conjugated goat anti-human Fc (Jackson ImmunoResearch) for B7-H3 scFv.hFc.

    Techniques: Functional Assay, Binding Assay, Immunofluorescence, Staining, Microscopy, Enzyme-linked Immunosorbent Assay

    Activity of TanCAR-T cells against tumor cells expressing CD70 and/or B7-H3. (A) Four-hour 51 Cr cytotoxicity assays of TanCAR-T cells against tumor cells expressing CD70 and/or B7-H3, compared with unispecific CAR and NT T cells. (B) Analysis of IFNγ and IL2 secretion level from supernatants of co-cultures of TanCAR, B7-H3 CAR, CD70 CAR 2 and NT T cells with multiple tumor cells, as detected by ELISA. Shown are pooled data from 3 independent experiments done in triplicates.

    Journal: Theranostics

    Article Title: Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors

    doi: 10.7150/thno.43991

    Figure Lengend Snippet: Activity of TanCAR-T cells against tumor cells expressing CD70 and/or B7-H3. (A) Four-hour 51 Cr cytotoxicity assays of TanCAR-T cells against tumor cells expressing CD70 and/or B7-H3, compared with unispecific CAR and NT T cells. (B) Analysis of IFNγ and IL2 secretion level from supernatants of co-cultures of TanCAR, B7-H3 CAR, CD70 CAR 2 and NT T cells with multiple tumor cells, as detected by ELISA. Shown are pooled data from 3 independent experiments done in triplicates.

    Article Snippet: Tumor cell surface expression of CD70 and B7-H3 were detected using CD70 scFv.mFc and B7-H3 scFv.hFc chimeric proteins followed by Cy3-conjuncted goat anti-mouse Fc (Proteintech) for CD70 scFv.hFc and Alexa Fluor 594-conjugated goat anti-human Fc (Jackson ImmunoResearch) for B7-H3 scFv.hFc.

    Techniques: Activity Assay, Expressing, Enzyme-linked Immunosorbent Assay

    Antitumor response of TanCAR-T cells against CD70 and B7-H3 positive tumors in vivo . (A) The treatment scheme showed the timing of subcutaneous injection of tumor cells, vein-tail injection of CAR-T cells T cells and in vivo optical imaging. (B) Antitumor response of TanCAR-T cells in human subcutaneous xenograft models. NCI-H460.ffLuc or A375.ffLuc tumor bearing (confirmed by imaging 6 days after tumor implantation, 8/group) mice were adoptively transferred through tail vein injection with NT, CD70 CAR 2 , B7-H3 CAR or high/low doses (5×10 6 or 1×10 6 /mouse) of TanCAR T cells on 7 days and 10 days post tumor inoculation. (C) Tumor growth was measured weekly by using Living Image software, and mean values per treated group were shown. (D) Kaplan-Meier survival curve were performed 75 days after T cells injection. Mice treated with TanCAR-T cells had a significantly longer survival probability in comparison with mice with NT, CD70 CAR 2 or B7-H3 CAR-T cells.

    Journal: Theranostics

    Article Title: Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors

    doi: 10.7150/thno.43991

    Figure Lengend Snippet: Antitumor response of TanCAR-T cells against CD70 and B7-H3 positive tumors in vivo . (A) The treatment scheme showed the timing of subcutaneous injection of tumor cells, vein-tail injection of CAR-T cells T cells and in vivo optical imaging. (B) Antitumor response of TanCAR-T cells in human subcutaneous xenograft models. NCI-H460.ffLuc or A375.ffLuc tumor bearing (confirmed by imaging 6 days after tumor implantation, 8/group) mice were adoptively transferred through tail vein injection with NT, CD70 CAR 2 , B7-H3 CAR or high/low doses (5×10 6 or 1×10 6 /mouse) of TanCAR T cells on 7 days and 10 days post tumor inoculation. (C) Tumor growth was measured weekly by using Living Image software, and mean values per treated group were shown. (D) Kaplan-Meier survival curve were performed 75 days after T cells injection. Mice treated with TanCAR-T cells had a significantly longer survival probability in comparison with mice with NT, CD70 CAR 2 or B7-H3 CAR-T cells.

    Article Snippet: Tumor cell surface expression of CD70 and B7-H3 were detected using CD70 scFv.mFc and B7-H3 scFv.hFc chimeric proteins followed by Cy3-conjuncted goat anti-mouse Fc (Proteintech) for CD70 scFv.hFc and Alexa Fluor 594-conjugated goat anti-human Fc (Jackson ImmunoResearch) for B7-H3 scFv.hFc.

    Techniques: In Vivo, Injection, Optical Imaging, Imaging, Tumor Implantation, Software